🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Isabelle Fajac

Université Paris Cité

ORCID: 0000-0002-1532-1486

Also affiliated with Sorbonne Paris Cité, Assistance Publique – Hôpitaux de Paris

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 6%percentile
0.299Author DataRank

Indexed papers

1in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Cystic Fibrosis Microbiome-directed Antibiotic Therapy Trial in Exacerbations Results Stratified (CFMATTERS): results of a multicentre randomised controlled trial

European Respiratory Journal(2025)10.1183/13993003.02443-2024
Top 55%
0.299DataRank
Top 55%5 citations

G.G. Einarsson, K. Deasy, Darren Dahly, Pradeep K. Singh, Peter Barry +18 more

Papers

Driven by 6 papers — median percentile 45. Top paper: “Triple Therapy for Cystic Fibrosis Phe508del –Gating and –Residual Function Genotypes”.

Triple Therapy for Cystic Fibrosis Phe508del –Gating and –Residual Function Genotypes

New England Journal of Medicine(2021)10.1056/nejmoa2100665
N/A
7.1DataRank · unranked
277 citations

Marcus Mall, Antonio Álvarez, Carla Colombo, Karin M. de Winter‐de Groot, Isabelle Fajac +17 more

Understanding and addressing the needs of people with cystic fibrosis in the era of CFTR modulator therapy

The Lancet Respiratory Medicine(2023)10.1016/s2213-2600(23)00324-7
N/A
0.604DataRank · unranked
55 citations

Susan E. Birket, John P. Clancy, D.G. Downey, John F. Engelhardt, Isabelle Fajac +8 more

Building global development strategies for cf therapeutics during a transitional cftr modulator era

Journal of Cystic Fibrosis(2020)10.1016/j.jcf.2020.05.011
N/A
0.520DataRank · unranked
31 citations

Silke van Koningsbruggen‐Rietschel, David P. Nichols, Donald R. VanDevanter, Jane C. Davies, T. Lee +20 more

Empire-CF study: A phase 2 clinical trial of leukotriene A4 hydrolase inhibitor acebilustat in adult subjects with cystic fibrosis

Journal of Cystic Fibrosis(2021)10.1016/j.jcf.2021.08.007
N/A
0.464DataRank · unranked
21 citations

Michael W. Konstan, Jennifer L. Taylor‐Cousar, Isabelle Fajac, Alex Horsley, Sivagurunathan Sutharsan +11 more

Cystic Fibrosis Microbiome-directed Antibiotic Therapy Trial in Exacerbations Results Stratified (CFMATTERS): results of a multicentre randomised controlled trial

European Respiratory Journal(2025)10.1183/13993003.02443-2024
Top 55%
0.299DataRank
Top 55%5 citations

G.G. Einarsson, K. Deasy, Darren Dahly, Pradeep K. Singh, Peter Barry +18 more

Advancing the pipeline of cystic fibrosis clinical trials: a new roadmap with a global trial network perspective

The Lancet Respiratory Medicine(2023)10.1016/s2213-2600(23)00297-7
N/A
0DataRank · unranked
33 citations

John P. Clancy, Raksha Jain, Scott H. Donaldson, Isabelle Fajac, Christopher H. Goss +21 more